1. Home
  2. IMRN vs SCNX Comparison

IMRN vs SCNX Comparison

Compare IMRN & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • SCNX
  • Stock Information
  • Founded
  • IMRN 1994
  • SCNX 2010
  • Country
  • IMRN Australia
  • SCNX United States
  • Employees
  • IMRN N/A
  • SCNX N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • SCNX Other Pharmaceuticals
  • Sector
  • IMRN Health Care
  • SCNX Health Care
  • Exchange
  • IMRN Nasdaq
  • SCNX Nasdaq
  • Market Cap
  • IMRN 9.2M
  • SCNX 14.4M
  • IPO Year
  • IMRN N/A
  • SCNX 2020
  • Fundamental
  • Price
  • IMRN $1.76
  • SCNX $1.60
  • Analyst Decision
  • IMRN Strong Buy
  • SCNX
  • Analyst Count
  • IMRN 1
  • SCNX 0
  • Target Price
  • IMRN $5.00
  • SCNX N/A
  • AVG Volume (30 Days)
  • IMRN 23.5K
  • SCNX 176.5K
  • Earning Date
  • IMRN 07-15-2025
  • SCNX 08-10-2025
  • Dividend Yield
  • IMRN N/A
  • SCNX N/A
  • EPS Growth
  • IMRN N/A
  • SCNX N/A
  • EPS
  • IMRN N/A
  • SCNX N/A
  • Revenue
  • IMRN $4,048,286.00
  • SCNX $146,901.00
  • Revenue This Year
  • IMRN N/A
  • SCNX N/A
  • Revenue Next Year
  • IMRN N/A
  • SCNX N/A
  • P/E Ratio
  • IMRN N/A
  • SCNX N/A
  • Revenue Growth
  • IMRN 82.90
  • SCNX N/A
  • 52 Week Low
  • IMRN $1.50
  • SCNX $0.69
  • 52 Week High
  • IMRN $2.87
  • SCNX $23.77
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 48.56
  • SCNX N/A
  • Support Level
  • IMRN $1.67
  • SCNX N/A
  • Resistance Level
  • IMRN $1.78
  • SCNX N/A
  • Average True Range (ATR)
  • IMRN 0.10
  • SCNX 0.00
  • MACD
  • IMRN -0.01
  • SCNX 0.00
  • Stochastic Oscillator
  • IMRN 49.97
  • SCNX 0.00

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

About SCNX Scienture Holdings Inc. Common Stock

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.

Share on Social Networks: